

Candidiasis: New Approaches to Diagnosis and Treatment

CME POSTTEST

Instructions for Obtaining CME Credit

The following examination gives you the opportunity to assess your knowledge and understanding of the information presented in this activity.

To obtain 1.0 Category 1 credit:

- Print the Posttest/Evaluation and Answer Sheet.
- Complete the entire Posttest and personal information as requested, marking your answers on the answer sheet provided.
- Answer the Program Evaluation Questions.
- Mail or Fax the completed form (postmarked no later than **February 28, 2007**) to:

CANDIDIASIS SLIDES

c/o: Center for Bio-Medical Communication, Inc.
433 Hackensack Avenue, 9th Floor
Hackensack, NJ 07601
Fax: 201-342-7555

A CME certificate will be mailed to participants who achieve a score of 70% or greater. Please allow 3 to 4 weeks for the processing of your CME certificate.

Release date: February 2, 2006

Expiration date: February 28, 2007

For further information regarding CME credit, phone: 201-342-5300

Please use the answer sheet to indicate your responses.

1. Which of the following is the **least** common *Candida* species typically found in nosocomial candidemia?

- A) *C. albicans*
- B) *C. glabrata*
- C) *C. krusei*
- D) *C. parapsilosis*

2. Which of the following is the **most** common isolate found in non-breakthrough candidemias?

- A) *C. albicans*
- B) *C. glabrata*
- C) *C. krusei*
- D) *C. parapsilosis*

3. Which of the following *Candida* species is the most important concern in breakthrough candidemia?

- A) *C. albicans*
- B) *C. glabrata*
- C) *C. krusei*
- D) *C. parapsilosis*

4. The *Candida* biofilm is most susceptible to which of the following agents?
- A) amphotericin
 - B) echinocandin
 - C) fluconazole
 - D) polyene
5. Which of the following is true? In overall *Candida* infections over time,
- A) prevalence of *C. albicans* is decreasing, while prevalence of *C. glabrata* and *C. krusei* is increasing
 - B) prevalence of *C. albicans* is increasing, while prevalence of *C. glabrata* and *C. krusei* is decreasing
 - C) prevalence of *C. albicans*, *C. glabrata*, and *C. krusei* has increased
 - D) prevalence of *C. albicans*, *C. glabrata*, and *C. krusei* has decreased
6. For real-time disk diffusion testing, which of the following are most commonly available?
- A) caspofungin disks
 - B) echinocandin disks
 - C) fluconazole disks
 - D) voriconazole disks
7. Echinocandins are effective against which of the following?
- A) *Candida*, *Aspergillus*, *Cryptococcus*, and Zygomycetes
 - B) *Candida*, *Aspergillus*, and Zygomycetes, but not *Cryptococcus*
 - C) *Candida*, *Aspergillus*, and *Cryptococcus*, but not Zygomycetes
 - D) *Candida* and *Aspergillus*, but not *Cryptococcus* and Zygomycetes
8. Which are characteristics of echinocandins in *Candida* esophagitis?
- A) Rapid resolution of lesions
 - B) Activity versus azole-resistant yeasts
 - C) More rapid relapse versus fluconazole
 - D) All the above
9. Under which circumstances would removing a vascular catheter generally be of least benefit in *Candida* infection?
- A) In neutropenic patients
 - B) In non–neutropenic patients
 - C) When *C. parapsilosis* is present
 - D) All the above
10. In treating urinary tract Candidiasis, which of the following agents produces the highest concentration in the urine?
- A) caspofungin
 - B) fluconazole
 - C) micafungin
 - D) voriconazole

Candidiasis: New Approaches to Diagnosis and Treatment

Answer Sheet and Program Evaluation

Circle the best answer and fax to 201-342-7555

- | | | | | | | | | | |
|----|---|---|---|---|-----|---|---|---|---|
| 1. | a | b | c | d | 6. | a | b | c | d |
| 2. | a | b | c | d | 7. | a | b | c | d |
| 3. | a | b | c | d | 8. | a | b | c | d |
| 4. | a | b | c | d | 9. | a | b | c | d |
| 5. | a | b | c | d | 10. | a | b | c | d |

1. The activity objectives were fully met:

Please select from: a. Strongly agree b. Agree c. Disagree d. Strongly disagree

- Discuss the prevalence of candidiasis among critically ill patients, and its impact on morbidity and mortality
a b c d
- Describe tools and techniques that facilitate early diagnosis
a b c d
- Assess newer therapeutic approaches for effective treatment, including echinocandins, extended-spectrum azoles, and drug combinations
a b c d

2. Did this CME activity provide fair balanced and scientifically rigorous information without commercial bias? ___Yes ___No

3. Did this activity provide practical information relevant to your practice?
___Yes ___No

4. Will this activity affect the way you treat patients? ___Yes ___No
If so, how? _____

5. How would you rate the overall educational context of the program?
___Excellent ___Good ___Fair ___Poor

Name _____ Degree _____ Specialty _____

Mailing Address _____

City _____ State _____ Zip _____

Phone _____ Fax _____ E-mail _____

I am entitled to the 1.0 credit awarded for this educational activity.

Signature _____ Date _____

Please do not include me on CBC's mailing list